# Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

> **NCT02979821** · PHASE2 · COMPLETED · sponsor: **Korean Association for the Study of Targeted Therapy** · enrollment: 6 (actual)

## Conditions studied

- HER2 Gene Mutation
- Adenocarcinoma Lung Stage IV

## Interventions

- **DRUG:** Poziotinib

## Key facts

- **NCT ID:** NCT02979821
- **Lead sponsor:** Korean Association for the Study of Targeted Therapy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979821, "Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02979821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*